Coinfecting viruses as determinants of HIV disease

Current HIV/AIDS Reports

Volumn 6, Issue 1, 2009, Pages 5-12

  Lisco, Andrea ^b   Vanpouille, Christophe ^b   Margolis, Leonid ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; EMCITRABINE; ENTECAVIR; LAMIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; JC VIRUS; MEASLES VIRUS; MICROORGANISM; MIXED INFECTION; MOLECULAR EVOLUTION; PATHOGENESIS; REVIEW; SUPERINFECTION; UPREGULATION; VIRUS TRANSMISSION; CLASSIFICATION; DISEASE COURSE; PATHOGENICITY; PATHOPHYSIOLOGY; VIROLOGY; VIRUS; VIRUS INFECTION;

ANTI-HIV AGENTS; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; VIRUS DISEASES; VIRUSES;

EID: 61449122149     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-009-0002-3     Document Type: Review

References (50)

1. Wenner M: Virology: the battle within. Nature 2008, 451:388-389.
2. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992, 41:1-19.
3. •• Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371. A seminal paper showing that chronic activation in individuals with HIV infection is due to the translocation of microbial products through the damaged gut mucosal barrier.
4. McGovern BH: The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection. Antivir Ther 2007, 12(Suppl 3):H3-H13.
5. Sulkowski MS: Management of hepatic complications in HIV-infected persons. J Infect Dis 2008, 197(Suppl 3):S279-S293.
6. Mohsen AH, Easterbrook P, Taylor CB, et al.: Hepatitis C and HIV-1 coinfection. Gut 2002, 51:601-608.
7. Weber R, Sabin CA, Friis-Moller N, et al.: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-1641.
8. Blackard JT, Kemmer N, Sherman KE: Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006, 44:15-22.
9. Laskus T, Radkowski M, Piasek A, et al.: Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000, 181:442-448.
10. Eckels DD, Wang H, Bian TH, et al.: Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol Rev 2000, 174:90-97.
11. • Yonkers NL, Rodriguez B, Post AB, et al.: HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells. J Infect Dis 2006, 194:391-400. An important paper demonstrating the functional defects of CD28 costimulation in patients with HIV-1/HCV coinfection.
12. • Kovacs A, Al-Harthi L, Christensen S, et al.: CD8+ T-cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008, 197:1402-1407. An important paper that demonstrates the increased immune activation and alteration in T-cell maturation in individuals with HIV-1/HCV coinfection. The paper also discusses the implications of these findings for HIV-1 disease progression.
13. Appay V, Dunbar PR, Callan M, et al.: Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002, 8:379-385.
14. •• Grossman Z, Meier-Schellersheim M, Paul WE, et al.: Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295. A seminal paper describing how the persistent activation progressively disrupts the functional organization of the immune system, ultimately resulting in AIDS.
15. Rey D, Vidinic-Moularde J, Meyer P, et al.: High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2000, 19:721-724.
16. • Zhang W, Chaloner K, Tillmann HL, et al.: Effect of early and late GB virus C viremia on survival of HIV-infected individuals: a meta-analysis. HIV Med 2006, 7:173-180. An important meta-analysis on the effect of HIV-1 coinfection with the GBV-C infection on the survival of indivduals with HIV-1 infection. GBV-C coinfection, in the advanced stages of HIV-1 disease, significantly increases survival.
17. Nunnari G, Nigro L, Palermo F, et al.: Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003, 139:26-30.
18. Stapleton JT, Chaloner K: GB virus C and survival in HIV-positive people. AIDS 2004, 18:2343-2346.
19. McLinden JH, Stapleton JT, Chang Q, et al.: Expression of the dengue virus type 2 NS5 protein in a CD4+ T cell line inhibits HIV replication. J Infect Dis 2008, 198:860-863.
20. Casoli C, Pilotti E, Bertazzoni U: Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev 2007, 9:140-149.
21. Brites C, Oliveira AS, Netto EM: Coinfection with HIV and human T lymphotropic virus type 1: what is the real impact on HIV disease? Clin Infect Dis 2005, 40:329-331.
22. Moriuchi H, Moriuchi M, Fauci AS: Factors secreted by human T lymphotropic virus type I (HTLV-I)-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: implications for in vivo coinfection with HTLV-I and HIV-1. J Exp Med 1998, 187:1689-1697.
23. Bogerd HP, Huckaby GL, Ahmed YF, et al.: The type I human T-cell leukemia virus (HTLV-I) Rex transactivator binds directly to the HTLV-I Rex and the type 1 human immunodeficiency virus Rev RNA response elements. Proc Natl Acad Sci U S A 1991, 88:5704-5708.
24. Bassani S, Lopez M, Toro C, et al.: Influence of human T-cell lymphotropic virus type 2 coinfection on virological and immunological parameters in HIV type 1-infected patients. Clin Infect Dis 2007, 44:105-110.
25. • Pilotti E, Elviri L, Vicenzi E, et al.: Postgenomic upregulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood 2007, 109:1850-1856. An interesting paper investigating the mechanisms and the significance of the upregulation of CCL3L1 expression during HTLV-2 infection.
26. Reeves JD, Doms RW: Human immunodeficiency virus type 2. J Gen Virol 2002, 83:1253-1265.
27. Travers K, Mboup S, Marlink R, et al.: Natural protection against HIV-1 infection provided by HIV-2. Science 1995, 268:1612- 1615.
28. Kokkotou EG, Sankale JL, Mani I, et al.: In vitro correlates of HIV-2-mediated HIV-1 protection. Proc Natl Acad Sci U S A 2000, 97:6797-6802.
29. Berger JR, Chauhan A, Galey D, et al.: Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol 2001, 7:329-338.
30. Kaniowska D, Kaminski R, Amini S, et al.: Cross-interaction between JC virus agnoprotein and human immunodeficiency virus type 1 (HIV-1) Tat modulates transcription of the HIV-1 long terminal repeat in glial cells. J Virol 2006, 80:9288-9299.
31. Moss WJ, Ryon JJ, Monze M, et al.: Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis 2002, 185:1035-1042.
32. Grivel JC, Garcia M, Moss WJ, et al.: Inhibition of HIV-1 replication in human lymphoid tissues ex vivo by measles virus. J Infect Dis 2005, 192:71-78.
33. Garcia M, Yu XF, Griffin DE, et al.: Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes. J Gen Virol 2008, 89:984-993.
34. •• Van de Perre P, Segondy M, Foulongne V, et al.: Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008, 8:490-497. An interesting review on the reciprocal interactions between HIV-1 and HSV-2. HIV-1 facilitates acquisition and reactivation of HSV and HSV in turn enhances HIV-1 acquisition and replication.
35. Fakioglu E, Wilson SS, Mesquita PM, et al.: Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008, 82:9337-9344.
36. Kovacs A, Schluchter M, Easley K, et al.: Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999, 341:77-84.
37. Biancotto A, Iglehart SJ, Lisco A, et al.: Upregulation of human cytomegalovirus by HIV type 1 in human lymphoid tissue ex vivo. AIDS Res Hum Retroviruses 2008, 24:453-462.
38. • Sheth PM, Danesh A, Sheung A, et al.: Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation. J Infect Dis 2006, 193:45-48. This interesting paper demonstrates that semen levels of HIV and CMV are closely correlated and suggests that prevention of CMV replication in the genital compartment could reduce HIV-1 shedding in semen.
39. Griffiths PD: CMV as a cofactor enhancing progression of AIDS. J Clin Virol 2006, 35:489-492.
40. Lusso P: HHV-6 and the immune system: mechanisms of immunomodulation and viral escape. J Clin Virol 2006, 37(Suppl 1):S4-S10.
41. Grivel JC, Ito Y, Faga G, et al.: Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med 2001, 7:1232-1235.
42. Lisco A, Grivel JC, Biancotto A, et al.: Viral interactions in human lymphoid tissue: human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol 2007, 81:708-717.
43. Arora A, Chiao E, Tyring SK: AIDS malignancies. Cancer Treat Res 2007, 133:21-67.
44. Caselli E, Galvan M, Santoni F, et al.: Human herpesvirus-8 (Kaposi's sarcoma-associated virus) ORF50 increases in vitro cell susceptibility to human immunodeficiency virus type 1 infection. J Gen Virol 2003, 84:1123-1131.
45. Boshoff C, Endo Y, Collins PD, et al.: Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997, 278:290-294.
46. van der Kuyl AC, Cornelissen M: Identifying HIV-1 dual infections. Retrovirology 2007, 4:67.
47. Ito Y, Grivel JC, Chen S, et al.: CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines. J Infect Dis 2004, 189:506-514.
48. McGeoch DJ, Dolan A, Ralph AC: Toward a comprehensive phylogeny for mammalian and avian herpesviruses. J Virol 2000, 74:10401- 10406.
49. •• Salazar-Gonzalez JF, Bailes E, Pham KT, et al.: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008, 82:3952-3970. An important paper that identifies the early founder viruses and investigates molecular pathways of early envelope diversification in individuals with HIV infection.
50. • Lisco A, Vanpouille C, Tchesnokov EP, et al.: Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008, 4:260-270. This paper demonstrates the possibility of exploiting metabolic activity of HHVs to convert an antiherpetic drug into an HIV suppressor in coinfected tissues.